Journal
ACG CASE REPORTS JOURNAL
Volume 4, Issue -, Pages -Publisher
AMER COLL GASTROENTEROLOGY
DOI: 10.14309/crj.2017.112
Keywords
-
Categories
Ask authors/readers for more resources
Checkpoint inhibitors are immune-stimulatory antibodies that have transformed the management and prognosis of individuals with metastatic melanoma and other cancers. Checkpoint inhibitor-induced colitis is an increasingly recognized immune-related adverse event that shares many of the same phenotypical, serological, and histological characteristics of both Crohn's disease and ulcerative colitis, suggesting that checkpoint inhibitor-induced colitis may represent a new inflammatory bowel disease phenotype. We report a 73-year-old man with metastatic melanoma who developed ipilimumab-induced colitis with subsequent transformation to Crohn's colitis-like phenotype after the addition of pembrolizumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available